Literature DB >> 10444341

Human phenylalanine hydroxylase gene expression in kidney and other nonhepatic tissues.

U Lichter-Konecki1, C M Hipke, D S Konecki.   

Abstract

Phenylalanine hydroxylase (PAH) is the key enzyme in phenylalanine metabolism. PAH deficiency results in hyperphenylalaninemia, leading to severe mental retardation in the classical form of the disease, phenylketonuria (PKU). Previously the expression of PAH could only unambiguously be demonstrated in human liver, whereas in rodents PAH expression has been established in kidney and liver. Reports concerning PAH activity in other human or rodent tissues were severely questioned by subsequent investigations such that they did not gain general recognition. Conducting Northern blot analyses, we detected the PAH transcript in RNA isolated from human liver, kidney, pancreas, and brain. PAH gene expression in human kidney was subsequently investigated by RNase protection assay analyses, RNA in situ hybridization, immunohistochemistry, enzyme assay, and cDNA isolation. These experiments allowed the conclusive verification of a functional PAH enzyme in human kidney. The primary structure of the kidney transcript corresponded to the structure of the liver transcript. Human kidney PAH may play a significant role in phenylalanine homeostasis of the organism, as impaired phenylalanine hydroxylation has been observed in renal failure and differences in the regulation of the kidney versus the liver enzyme have been indicated. These results provide new aspects to research into the basis for the heterogeneity of hyperphenylalaninemia phenotypes and establish that the expression of the human PAH gene is not limited to the liver. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10444341     DOI: 10.1006/mgme.1999.2880

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  21 in total

1.  Queuosine deficiency in eukaryotes compromises tyrosine production through increased tetrahydrobiopterin oxidation.

Authors:  Tatsiana Rakovich; Coilin Boland; Ilana Bernstein; Vimbai M Chikwana; Dirk Iwata-Reuyl; Vincent P Kelly
Journal:  J Biol Chem       Date:  2011-04-12       Impact factor: 5.157

2.  Tetrahydrobiopterin treatment reduces brain L-Phe but only partially improves serotonin in hyperphenylalaninemic ENU1/2 mice.

Authors:  Tanja Scherer; Gabriella Allegri; Christineh N Sarkissian; Ming Ying; Hiu Man Grisch-Chan; Anahita Rassi; Shelley R Winn; Cary O Harding; Aurora Martinez; Beat Thöny
Journal:  J Inherit Metab Dis       Date:  2018-03-08       Impact factor: 4.982

3.  Metabolomic profiling for identification of potential biomarkers in patients with dermatomyositis.

Authors:  Tie Zhang; Jing Xu; Yang Liu; Jia Liu
Journal:  Metabolomics       Date:  2019-05-13       Impact factor: 4.290

Review 4.  GCH1, BH4 and pain.

Authors:  Alban Latremoliere; Michael Costigan
Journal:  Curr Pharm Biotechnol       Date:  2011-10       Impact factor: 2.837

5.  Hepatic nuclear factor 1-alpha directs nucleosomal hyperacetylation to its tissue-specific transcriptional targets.

Authors:  M Párrizas; M A Maestro; S F Boj; A Paniagua; R Casamitjana; R Gomis; F Rivera; J Ferrer
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

6.  Identification of Insulin Resistance Biomarkers in Metabolic Syndrome Detected by UHPLC-ESI-QTOF-MS.

Authors:  Leen Oyoun Alsoud; Nelson C Soares; Hamza M Al-Hroub; Muath Mousa; Violet Kasabri; Nailya Bulatova; Maysa Suyagh; Karem H Alzoubi; Waseem El-Huneidi; Bashaer Abu-Irmaileh; Yasser Bustanji; Mohammad H Semreen
Journal:  Metabolites       Date:  2022-06-01

Review 7.  What we know that could influence future treatment of phenylketonuria.

Authors:  C N Sarkissian; A Gámez; C R Scriver
Journal:  J Inherit Metab Dis       Date:  2008-08-03       Impact factor: 4.982

Review 8.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

9.  Chronic kidney disease in adolescent and adult patients with phenylketonuria.

Authors:  Julia B Hennermann; Sylvia Roloff; Jutta Gellermann; Ilka Vollmer; Elke Windt; Barbara Vetter; Ursula Plöckinger; Eberhard Mönch; Uwe Querfeld
Journal:  J Inherit Metab Dis       Date:  2012-11-09       Impact factor: 4.982

10.  The polar oxy-metabolome reveals the 4-hydroxymandelate CoQ10 synthesis pathway.

Authors:  Robert S Banh; Esther S Kim; Quentin Spillier; Douglas E Biancur; Keisuke Yamamoto; Albert S W Sohn; Guangbin Shi; Drew R Jones; Alec C Kimmelman; Michael E Pacold
Journal:  Nature       Date:  2021-09-01       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.